Divis Laboratories in South Africa

Divi’s Laboratories Expands Global Footprint with Major Pharmaceutical Deal

Hyderabad, India – May 24, 2025

Divi’s Laboratories, a leading Indian pharmaceutical company, has secured a significant long-term manufacturing and supply agreement with a prominent global pharmaceutical firm. This partnership involves the production and supply of advanced pharmaceutical intermediates, marking a substantial milestone in Divi’s expansion strategy. (business-standard.com)

Strategic Investment to Boost Manufacturing Capacity

To fulfill the terms of this agreement, Divi’s Laboratories plans to invest between ₹650 crore and ₹750 crore in expanding its manufacturing facilities. This investment will be financed through capacity reservation advances, which will be received in phases from the customer. The company anticipates that this expansion will not only strengthen its supply chain reliability but also enhance its position in the custom synthesis sector. (business-standard.com)

Financial Performance and Shareholder Returns

In its latest financial report for the quarter ending March 31, 2025, Divi’s Laboratories reported a 23.04% increase in net profit, reaching ₹662 crore, compared to ₹538 crore in the same quarter the previous year. Revenue from operations grew by 12.24% to ₹2,585 crore. The company’s board has recommended a final dividend of ₹30 per equity share (1,500% on a face value of ₹2 each) for the fiscal year 2023-24, with the record date set for August 2, 2024. (etnownews.com)

Market Performance and Stock Highlights

Following the announcement of the new global partnership, Divi’s Laboratories’ shares reached a record high, rising by as much as 4.37% to ₹6,764 per share. This surge reflects investor confidence in the company’s strategic direction and financial health. (businesstoday.in)

READ Tech Mahindra Expands Its Footprint: New Innovations in South Africa’s Tech Landscape

Regulatory Update

In December 2024, Divi’s Laboratories addressed concerns regarding a U.S. District Court ruling that could pave the way for generic competition for Novartis’s heart failure drug, Entresto, a key product in Divi’s contract manufacturing portfolio. The company stated that it does not anticipate any material impact from this development. (cnbctv18.com)

Conclusion

Divi’s Laboratories continues to strengthen its global presence through strategic partnerships and investments, demonstrating robust financial performance and a commitment to delivering value to its shareholders.

For more information, visit Divi’s Laboratories Official Website.